Featured Research Search Results
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment
Clinicaltrials.gov identifier:
NCT07062965
Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment
Comparing Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (Rasolute 303)
Clinicaltrials.gov identifier:
NCT07491445
Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer
Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back
Clinicaltrials.gov identifier:
NCT06888921
Treatment
Study for relapsed platinum-sensitive ovarian cancer
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
Clinicaltrials.gov identifier:
NCT06974110
Treatment
Treatment study for people with advanced or metastatic cancers
Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)
Clinicaltrials.gov identifier:
NCT05946213
Treatment
Phase 3 treatment study for high-risk prostate cancer
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
Clinicaltrials.gov identifier:
NCT06782932
Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Treating Advanced Endometrial Cancer with Targeted Therapies (ComboMATCH)
Clinicaltrials.gov identifier:
NCT05554328
Treatment
Phase 2 treatment study for recurrent endometrial cancer
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
Clinicaltrials.gov identifier:
NCT05498272
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)
Clinicaltrials.gov identifier:
NCT07218809
Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Clinicaltrials.gov identifier:
NCT05059444
Treatment
Post-treatment study to monitor for recurrence
Comparing an Experimental Drug Puxi-Sam with Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)
Clinicaltrials.gov identifier:
NCT07044336
Treatment
Phase 3 treatment study for metastatic endometrial cancer
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
Clinicaltrials.gov identifier:
NCT07397338
Treatment
Phase 1/2 treatment study for solid tumors with a RAS mutation
Comparing a New Drug, Palazestrant, to Standard Treatment for Advanced Breast Cancer
Clinicaltrials.gov identifier:
NCT06016738
Treatment
Phase 3 study for ER-positive, HER2-negative advanced or metastatic breast cancer
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
Clinicaltrials.gov identifier:
NCT06128551
Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
Clinicaltrials.gov identifier:
NCT06411691
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
Clinicaltrials.gov identifier:
NCT05879926
Treatment
Phase 3 study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
Sponsored By
